JP2017507181A5 - - Google Patents

Download PDF

Info

Publication number
JP2017507181A5
JP2017507181A5 JP2016570199A JP2016570199A JP2017507181A5 JP 2017507181 A5 JP2017507181 A5 JP 2017507181A5 JP 2016570199 A JP2016570199 A JP 2016570199A JP 2016570199 A JP2016570199 A JP 2016570199A JP 2017507181 A5 JP2017507181 A5 JP 2017507181A5
Authority
JP
Japan
Prior art keywords
seq
protein
uspa2
immunogenic composition
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016570199A
Other languages
English (en)
Japanese (ja)
Other versions
JP6585085B2 (ja
JP2017507181A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/051308 external-priority patent/WO2015125118A1/en
Publication of JP2017507181A publication Critical patent/JP2017507181A/ja
Publication of JP2017507181A5 publication Critical patent/JP2017507181A5/ja
Application granted granted Critical
Publication of JP6585085B2 publication Critical patent/JP6585085B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016570199A 2014-02-24 2015-02-20 Uspa2タンパク質構築物およびそれらの使用 Expired - Fee Related JP6585085B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461943909P 2014-02-24 2014-02-24
US61/943,909 2014-02-24
US201461946937P 2014-03-03 2014-03-03
US201461946932P 2014-03-03 2014-03-03
US61/946,932 2014-03-03
US61/946,937 2014-03-03
PCT/IB2015/051308 WO2015125118A1 (en) 2014-02-24 2015-02-20 Uspa2 protein constructs and uses thereof

Publications (3)

Publication Number Publication Date
JP2017507181A JP2017507181A (ja) 2017-03-16
JP2017507181A5 true JP2017507181A5 (enExample) 2018-04-05
JP6585085B2 JP6585085B2 (ja) 2019-10-02

Family

ID=52629643

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016570199A Expired - Fee Related JP6585085B2 (ja) 2014-02-24 2015-02-20 Uspa2タンパク質構築物およびそれらの使用

Country Status (28)

Country Link
US (3) US10040832B2 (enExample)
EP (2) EP3498292B1 (enExample)
JP (1) JP6585085B2 (enExample)
KR (1) KR102515835B1 (enExample)
CN (2) CN106061995A (enExample)
AU (1) AU2015220369B2 (enExample)
BE (1) BE1022345A9 (enExample)
BR (1) BR112016019525B1 (enExample)
CA (1) CA2939862C (enExample)
CY (2) CY1121535T1 (enExample)
DK (2) DK3110438T3 (enExample)
EA (1) EA034352B1 (enExample)
ES (2) ES2715674T3 (enExample)
HR (2) HRP20211926T1 (enExample)
HU (2) HUE057505T2 (enExample)
IL (1) IL246994B (enExample)
LT (2) LT3498292T (enExample)
ME (1) ME03335B (enExample)
MX (1) MX376079B (enExample)
PL (2) PL3498292T3 (enExample)
PT (2) PT3110438T (enExample)
RS (2) RS58451B1 (enExample)
SG (1) SG11201606272PA (enExample)
SI (2) SI3498292T1 (enExample)
SM (2) SMT201900166T1 (enExample)
TW (1) TW201620927A (enExample)
UY (1) UY36006A (enExample)
WO (1) WO2015125118A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201620927A (zh) * 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Uspa2蛋白質構築體及其用途
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
JP2020515587A (ja) * 2017-03-31 2020-05-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 免疫原性組成物、使用及び処置方法
FR3066920A1 (fr) 2017-05-30 2018-12-07 Glaxosmithkline Biologicals S.A. Nouveaux procedes de fabrication d'un adjuvant
MX2020001820A (es) * 2017-08-14 2020-03-20 Glaxosmithkline Biologicals Sa Metodos para reforzar las respuestas inmunitarias.
CN111670044A (zh) 2017-12-01 2020-09-15 葛兰素史密丝克莱恩生物有限公司 皂苷纯化
GB201803692D0 (en) * 2018-03-08 2018-04-25 Glaxosmithkline Biologicals Sa Immunogenic composition
CA3107077A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
US20210220462A1 (en) * 2018-08-23 2021-07-22 Glaxosmithkline Biologicals Sa Immunogenic proteins and compositions
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
WO2020212461A1 (en) 2019-04-18 2020-10-22 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
JP7640473B2 (ja) 2019-06-05 2025-03-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
JP2022543264A (ja) * 2019-08-05 2022-10-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム プロテインdポリペプチドを含む組成物を調製するプロセス
CA3148924A1 (en) 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2021048159A1 (en) 2019-09-11 2021-03-18 Glaxosmithkline Biologicals Sa Assay
JP2024510717A (ja) 2021-02-22 2024-03-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物、使用及び方法
EP4558170A1 (en) 2022-07-19 2025-05-28 GlaxoSmithKline Biologicals S.A. Continuous process for vaccine production

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69327599T2 (de) 1992-06-25 2000-08-10 Smithkline Beecham Biolog Adjuvantien enthaltende Impfstoffzusammensetzung
WO1994021292A1 (en) 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE69740108D1 (de) * 1996-12-20 2011-03-10 Univ Texas Moraxella catarrhalis antigene uspa1 und uspa2
ES2298269T3 (es) 2000-09-26 2008-05-16 Idera Pharmaceuticals, Inc. Modulacion de la actividad inmunoestimulante de analogos oligonucleotidicos inmunoestimulantes mediante cambios quimicos posicionales.
AU2002258734A1 (en) * 2001-04-13 2002-10-28 Wyeth Holdings Corporation Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
CA2452836C (en) * 2001-07-27 2012-11-27 Chiron Srl Meningococcus adhesins nada, app and orf 40
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
JP5269594B2 (ja) * 2005-08-10 2013-08-21 アルネ・フオシユグレン・アー・ベー モラクセラ・カタラーリスと上皮細胞、細胞外マトリックス蛋白質及び補体系の相互作用
ZA200800891B (en) * 2005-08-10 2009-06-24 Arne Forsgren Ab Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
SG175492A1 (en) * 2006-01-17 2011-11-28 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein e; pe)
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
KR20140066126A (ko) * 2011-05-11 2014-05-30 리스벡 헬스케어 스웨덴 에이비 단백질 f - 라미닌 및 비트로넥틴 결합 특성을 갖는 신규한 헤모필러스 인플루엔자 부착분자
TW201620927A (zh) * 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Uspa2蛋白質構築體及其用途

Similar Documents

Publication Publication Date Title
JP2017507181A5 (enExample)
JP2016509011A5 (enExample)
JP2010166916A5 (enExample)
JP2012126742A5 (enExample)
JP2008538183A5 (enExample)
ES2563646T3 (es) Composiciones y métodos relacionados con variantes de la proteína A (SpA)
CN106659777A8 (zh) 免疫原性组合产品
HRP20200466T1 (hr) Fuzijski proteini i kombinacijska cjepiva
HRP20211926T1 (hr) Konstrukti proteina uspa2 i njihova upotreba
JP2014530010A5 (enExample)
JP2017048194A5 (enExample)
JP2013543499A5 (enExample)
JP2008525033A5 (enExample)
JP2010273685A5 (enExample)
JP2012095652A5 (enExample)
JP2014000092A5 (enExample)
BRPI0922867B8 (pt) glicoproteina de fusão (f) de vírus sincicial respiratório (rsv), ácido nucleico isolado, célula hospedeira, composição de vacina e micela purificada
RU2017104529A (ru) Композиции neisseria meningitidis и способы их применения
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
JP2014051497A5 (enExample)
JP2012082206A5 (enExample)
JP2015533791A5 (enExample)
JP2016508503A5 (enExample)
WO2011094357A3 (en) Repiratory virus epitopes templated into double stranded coiled -coils and use thereof in immunization
JP2015536312A5 (enExample)